UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Nature medicine, 2022-01, Vol.28 (1), p.144-153

2022

Volltextzugriff (PDF)

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Clinical cancer research, 2024-07, Vol.30 (13), p.2709-2718

2024

Volltextzugriff (PDF)

Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2023-11, Vol.37 (6), p.891-899

2023

Volltextzugriff (PDF)

Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2024-02, Vol.188, p.107442-107442, Article 107442

2024

Volltextzugriff (PDF)

Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease

Oral oncology, 2018-03, Vol.78, p.151-155

2018

Volltextzugriff (PDF)

Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer

Oral oncology, 2019-10, Vol.97, p.18-22

2019

Volltextzugriff (PDF)

Concurrent Radiotherapy and Triweekly Carboplatin for the Definitive Treatment of Locally Advanced Laryngeal Carcinoma

American journal of clinical oncology, 2018-06, Vol.41 (6), p.595-600

2018

Volltextzugriff (PDF)

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

The lancet. Gastroenterology & hepatology, 2024-08, Vol.9 (8), p.694-704

2024

Volltextzugriff (PDF)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Communications medicine, 2023-02, Vol.3 (1), p.14-14, Article 14

2023

Volltextzugriff (PDF)

Approaches to gene therapy for human immunodeficiency virus infection

Human gene therapy, 2001-06, Vol.12 (9), p.1013-1019

2001

Volltextzugriff (PDF)

Disparities in clinical trials participation in a vertically integrated care delivery system

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.128-128

2021

Volltextzugriff (PDF)

Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3552-3552

2022

Volltextzugriff (PDF)

Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9047-9047

2023

Volltextzugriff (PDF)

Development of lentiviral vectors for gene therapy for human diseases

Blood, 2000-04, Vol.95 (8), p.2499-2504

2000

Volltextzugriff (PDF)

First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.250-250

2024

Volltextzugriff (PDF)

NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3564-3564

2022

Volltextzugriff (PDF)

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS G12C mutation

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.519-519

2022

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5012-5012

2023

Volltextzugriff (PDF)

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5019-5019

2022

Volltextzugriff (PDF)

Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer

Current genomics, 2004-01, Vol.5 (1), p.19-35

Buchschacher, Jr, Gary

2004

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(45)
Dissertationen
(1)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Humans
(14)
Oncology
(9)
Aids/hiv
(8)
Aged
(5)
Biological And Medical Sciences
(5)
Hiv-1 - Genetics
(5)
Human Immunodeficiency Virus
(5)
Human Immunodeficiency Virus 1
(5)
Middle Aged
(5)
Mutation
(5)
Patients
(5)
Virology
(5)
Fundamental And Applied Biological Sciences. Psychology
(4)
Gene Therapy
(4)
Immunotherapy
(4)
Medicine, Research & Experimental
(4)
Metastases
(4)
Metastasis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer

Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease

Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial

Concurrent Radiotherapy and Triweekly Carboplatin for the Definitive Treatment of Locally Advanced Laryngeal Carcinoma

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Approaches to gene therapy for human immunodeficiency virus infection

Disparities in clinical trials participation in a vertically integrated care delivery system

Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer

Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)

Development of lentiviral vectors for gene therapy for human diseases

First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study

NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS G12C mutation

Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial

Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer

Suchergebnisse filtern